Binimetinib
Who holds supplier records for Binimetinib? 4 organisations hold a current record for Binimetinib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (3) and China (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Binimetinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/binimetinib
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
3 of the 4 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Binimetinib expires 18 Oct 2033. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Binimetinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 36434, 43850, 43851 · latest filing Mar 2026
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 36600 · latest filing Dec 2021
- VALARY LAB PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 40805 · latest filing Nov 2024
- Zhejiang Ausun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 44050 · latest filing Jun 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Binimetinib). The latest listed patent expires 18 Oct 2033. The latest listed exclusivity ended 11 Oct 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Binimetinib is a small molecule inhibitor of MEK1 and MEK2, proteins that play a key role in the mitogen-activated protein kinase (MAPK) signaling pathway involved in cell proliferation. It is used in the treatment of certain types of melanoma in combination with other therapies.
Chemical identity
- IUPAC name
- 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
- Canonical SMILES
- CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
- InChIKey
- ACWZRVQXLIRSDF-UHFFFAOYSA-N
- Synonyms
- Mektovi API, arry-162, arry-438162, mek-162, mek162, mektovi, nvp-mek162
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Binimetinib?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Binimetinib: MSN Laboratories Private Limited (India), Alembic Pharmaceuticals Limited (India), VALARY LAB PRIVATE LIMITED (India) and Zhejiang Ausun Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Binimetinib Drug Master Files are active?
MSN Laboratories Private Limited (DMF 36434, 43850), Alembic Pharmaceuticals Limited (DMF 36600), VALARY LAB PRIVATE LIMITED (DMF 40805) and Zhejiang Ausun Pharmaceutical Co., Ltd. (DMF 44050). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Binimetinib?
Yes. The latest patent listed for an approved US product containing Binimetinib expires 18 Oct 2033, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Binimetinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Binimetinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.